Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to
prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin
chemotherapy.